**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 63126

**Manuscript Type:** REVIEW

**Conundrum of vitamin D on glucose and fuel homeostasis**

Chang Villacreses MM *et al*. Vitamin D on glucose and fuel homeostasis

Maria Mercedes Chang Villacreses, Rudruidee Karnchanasorn, Panadeekarn Panjawatanan, Horng-Yih Ou, Ken C Chiu

**Maria Mercedes Chang Villacreses, Panadeekarn Panjawatanan, Ken C Chiu,** Department of Clinical Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, Duarte, CA 91010, United States

**Maria Mercedes Chang Villacreses, Ken C Chiu,** Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, United States

**Rudruidee Karnchanasorn,** Division of Endocrinology, Department of Medicine, University of Kansas Medical Center, Kansas City, KS 66160, United States

**Panadeekarn Panjawatanan,** Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY 13326, United States

**Horng-Yih Ou,** Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan 700, Taiwan

**Author contributions:** Chang Villacreses MM,Chiu KC, Karnchanasorn R, and Ou HYdeveloped the central theme and concepts of this manuscript; Panjawatanan P collected the data and participated in data analyses with Chang Villacreses MM, Chiu KC, Karnchanasorn R, and Ou HY; Chang Villacreses MM and Chiu KCprepared the first draft of manuscript; Chang Villacreses MM, Chiu KC, Karnchanasorn R, and Ou HY took part in critical review and revision of manuscript.

**Corresponding author: Ken C Chiu, FACE, FACP, MD, Professor,** Department of Clinical Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, United States. kenchiumd@gmail.com

**Received:** January 26, 2021

**Revised:** May 10, 2021

**Accepted:** August 5, 2021

**Published online:** September 15, 2021

**Abstract**

As an endocrine hormone, vitamin D plays an important role in bone health and calcium homeostasis. Over the past two decades, the non-calcemic effects of vitamin D were extensively examined. Although the effect of vitamin D on beta cell function were known for some time, the effect of vitamin D on glucose and fuel homeostasis has attracted new interest among researchers. Yet, to date, studies remain inconclusive and controversial, in part, due to a lack of understanding of the threshold effects of vitamin D. In this review, a critical examination of interventional trials of vitamin D in prevention of diabetes is provided. Like use of vitamin D for bone loss, the benefits of vitamin D supplementation in diabetes prevention were observed in vitamin D-deficient subjects with serum 25-hydroxyvitamin D < 50 nmol/L (20 ng/mL). The beneficial effect from vitamin D supplementation was not apparent in subjects with serum 25-hydroxyvitamin D > 75 nmol/L (30 ng/mL). Furthermore, no benefit was noted in subjects that achieved serum 25-hydroxyvitamin D > 100 nmol/L (40 ng/mL). Further studies are required to confirm these observations.

**Key Words:** Vitamin D; Glucose metabolism; Diabetes mellitus; Insulin sensitivity; Beta cell function

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Chang Villacreses MM, Karnchanasorn R, Panjawatanan P, Ou HY, Chiu KC. Conundrum of vitamin D on glucose and fuel homeostasis. *World J Diabetes* 2021; 12(9): 1363-1385

**URL:** https://www.wjgnet.com/1948-9358/full/v12/i9/1363.htm

**DOI:** https://dx.doi.org/10.4239/wjd.v12.i9.1363

**Core Tip:** Vitamin D deficiency is a well-recognized health issue and contributes to bone loss and calcium dysregulation. Evidence suggests that excess vitamin D is not in and of itself of therapeutic benefit. Available clinical data suggests that vitamin D supplementation appears to limit the development of diabetes in vitamin D deficient subjects. However, no benefit was observed in non-vitamin D deficient subjects. Furthermore, overreplacement of vitamin D is of no beneficial effect and could possibly be harmful.

**INTRODUCTION**

The potential role of vitamin D deficiency induced by migration of human beings has been suggested to be involved in human evolution and various modern health conditions[1]. The history prospective of vitamin D evaluation will enhance our understanding of the development in this field. The role of dietary deficiency in the pathogenesis of rickets was established by Platt[2] in 1919. Although it was thought to be caused by vitamin A deficiency initially, McCollum *et al*[3] identified a vitamin deficiency other than vitamin A that caused rickets in 1922. Since vitamin A, B, and C were already identified, the new molecule was named as vitamin D[4].

Beginning with its discovery in 1922, scientific publications focusing upon vitamin D numbered no more than some 10 per year but this increased to 35 per year by 1945 (Figure 1). As knowledge of the structure, molecular biology and function of vitamin D increased[5,6], there was a concurrent increase in vitamin D-specific publications. With the observations of the non-calcemic effects of vitamin D[7], vitamin D-focused publications peaked at 5152 in 2017. Recently, the role of vitamin D deficiency in relation to coronavirus disease 2019 (COVID-19) infection attracted attention[8].

***Vitamin D on bone health***

The role of vitamin D on calcium and bone metabolism was well-summarized[9]. There is no doubt about the association between rickets and vitamin D deficiency and the reversal and prevention of rickets with vitamin D supplementation. However, controversy still surrounds the efficacy of vitamin D supplementation upon bone mineral density and fracture prevention. Multiple studies failed to demonstrate any benefit from vitamin D supplementation[10-12] and a systematic review and meta-analysis also failed to confirm any beneficial effect on bone density or fracture prevention from vitamin D supplement[13]. Nevertheless, placebo-control randomized clinical trials revealed a threshold effect of vitamin D[14,15] with no benefit observed on the subjects with baseline 25-hydroxyvitamin D level ≥ 75 nmol/L (30 ng/mL). Furthermore, possible detrimental effects on bone mineral density were observed in subjects who received a higher dose of vitamin D (250 μg or 10000 IU daily) with a mean 25-hydroxyvitamin D of 200 nmol/L or 80 ng/mL[12]. While not conclusive, these data suggest that the optimal effects of vitamin D are found at a 25-hydroxyvitamin D level of 75 nmol/L (30 ng/mL).

***Vitamin D as a hormone***

Vitamins are defined as micronutrients that cannot be self-synthesized and that necessary for the proper function of key enzymatic processes. Consequently, vitamins must be obtained through the diet. Vitamin D is synthesized from cholesterol to 7-dehydrocholesterol, also known as pro-vitamin D3,in the skin through the action of ultraviolet radiation[16]. In addition, the liver forms 25-hydroxyvitamin D3, also known as pre-vitamin D3. To become an active compound, further hydroxylation in the kidney is required to form 1,25-dihydroxyvitaomin D3, which is a biologically active vitamin D. Then, 1,25-dihydroxyvitamin D is released into circulation to exert its effects on the target cells and promote calcium and bone homeostasis. Thus, vitamin D is a hormone and, like the pituitary-thyroid axis, has a complex natural history in the body (Table 1).

The half-life of thyroid hormone depends upon thyroid status[17]. The half-life for levothyroxine (T4) is 6-7 d in euthyroid subjects, 9-10 d in subjects with hypothyroidism, and 3-4 d in subjects with hyperthyroidism. The half-life of liothyronine (T3) is 18-24 h in euthyroid subjects, 12-16 h in hyperthyroid subjects, and 26-32 h in hypothyroid subjects. The half-life of vitamin D averages 15 h but depends upon of the type of vitamin D (cholecalciferol or vitamin D3 *vs* ergocalciferol or vitamin D2) and vitamin D binding protein concentration[18]. The half-life of 1,25-dihydroxyvitamin D is 10-20 h[19], while there is no information regarding the half-life of 1,25-dihydroxyvitamin D3 *vs* D2. Since 1,25-dihydroxyvitamin D is released into the blood and exerts its effects upon osteocytes to promote mineralization and on the gastrointestinal epithelium to increase calcium and phosphorus absorption, it is appropriate to classify vitamin D as a hormone.

**Evidence of non-calcemic effects**

In addition to the target organs, both the vitamin D receptor and 1alpha-hydroxylase (CYP27B1) are expressed in various other tissues[20], suggesting additional functions of vitamin D beyond bone metabolism and calcium homeostasis. Interestingly, the vitamin D receptor is expressed in the pancreatic islets[21], liver[22], muscle[23], and adipose tissue[24]. 1alpha-hydroxylase (CYP27B1) is expressed in pancreatic islets[25], liver[26], muscle[27], and adipose tissue[28]. Thus, it is possible that vitamin D could take part in glucose and fuel homeostasis.

In contrast to calcemic effects of vitamin D which is primary mediated by circulating 1,25-dihydroxyvitamin D produced in the kidney, the non-calcemic effects of vitamin D are mediated by circulating 25-hydroxyvitamin D through a paracrine or autocrine function[29]. Within the target cells or its vicinity, circulatory 25-hydroxyvitamin D enters cells and is converted to 1,25-dihydroxyvitamin D by the locally existing 1alpha-hydroxylase (CYP27B1). Hence, 25-hydroxyvitamin D is the key circulatory element for the non-calcemic effects of vitamin D whereas 1,25-dihydroxyvitamin D the promotes the calcemic effects.

**EFFECTS UPON CELL DIFFERENTIATION AND CELL PROLIFERATION**

***Colon, prostate, breast, and ovarian cancer***

A role for vitamin D in the pathogenesis of cancer was proposed in 1980[30] after it was observed that colon cancer rates were higher in the northern rather than the southern United States. The association of vitamin D deficiency with cancer, including breast[31], prostate[32], and colon cancer[33] was attributed to the ability of vitamin D to differentiation cells[34] and to suppress cell proliferative[35] along with other effects[36,37].

***Immunity, autoimmunity, and inflammation***

The risk of type 1 diabetes was reduced by vitamin D supplement in a birth-cohort study from Finland[38]. Furthermore, a polymorphism in the vitamin D receptor was associated with increased risk of type 1 diabetes[39]. Not unexpectedly, a role of vitamin D deficiency in the pathogenesis of type 1 diabetes was proposed[40]. In addition, the association of vitamin D deficiency with multiple sclerosis[41], systemic lupus erythematosus[42], and other autoimmune diseases[43] was attributed to the immunomodulatory and anti-inflammatory effects of vitamin D[44]. Furthermore, vitamin D plays an important role in the maintenance of B cell homeostasis[45], and vitamin D replacement may reduce B cell-mediated autoimmune disorders.

The role of vitamin D in the treatment of tuberculosis was appreciated with the observation that sun exposure altered the clinical presentation of tuberculosis[46]. Subsequently, vitamin D was administered as part of the treatment of tuberculosis[47]. Vitamin D deficiency was frequently observed in patient with untreated tuberculosis[48]. It is now known that Toll-like receptors up-regulate expression of the vitamin D receptor and the vitamin D-1-hydroxylase genes, leading to induction of the antimicrobial peptide cathelicidin and killing of intracellular Mycobacterium tuberculosis[49]. Thus, the role of vitamin D in fighting infection is established[50]. Further, vitamin D deficiency is associated with acute respiratory tract infection[51], bacterial vaginosis[52], pneumonia[53], foot infection in diabetics[54], chronic hepatitis C infection[55], and human immunodeficiency virus infection[56]. Recently, vitamin D deficiency was recognized as a risk factors for COVID-19 infection[57-61]. Thus, vitamin D could play a role in fighting infection.

An association between vitamin D receptor polymorphism and the severity of coronary artery disease was reported[62]. Deficiency was also noted to associate with an increased risk of myocardial infraction[63], hypertension[64], and stroke[65]. The mechanism proposed to account for these associations included activation of the renin-angiotensin system[66], coronary calcification[67], platelet activation and aggregation[68], increased proinflammatory cytokines[69], and vascular endothelial dysfunction[65].

***Fuel metabolism***

In patients with vitamin D deficiency and diabetes, vitamin D supplementation improved beta cell function and glucose tolerance[70]. An association between vitamin D deficiency and glucose intolerance and beta cell dysfunction was observed in east London Asians[71]. Similarly, alternations in vitamin D metabolism in obese subjects manifesting as low 25-hydroxyvitaimin D is well-recognized[72]. This topic will be reviewed in this article.

***Neuropsychiatric disorders***

Vitamin D deficiency was reported to be associated with depression[73], schizophrenia[74], autism[75], and Parkinson’s disease[76]. Various mechanisms have been reported to support a role of vitamin D in neuropsychiatric disorders. Vitamin D has a protective effect on dopaminergic neurons[77]. Vitamin D deficiency could result in altered synaptic plasticity through its effect on perineuronal nets leading to cognitive deficits[78]. Vitamin D deficiency alters brain protein expression in rats[79]. Furthermore, immunohistochemical study revealed the expression of vitamin D receptor and 1alpha-hydroxylase (CYP27B1) in various regions of human brain with the strong expression in the hypothalamus and in the large (presumably dopaminergic) neurons within the substantia nigra[80]. Thus, vitamin D deficiency could play a role in the pathogenesis of various neuropsychiatric disorders.

**Vitamin D replacement therapy**

***Source of vitamin D***

Vitamin D is available in two forms: ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). Ergocalciferol comes from plants in the form of ergosterol (provitamin D2). Ergosterol is an important component of mushrooms. Through ultraviolet b (UVB) irradiation, which can occur within mushroom or artificially, it becomes ergocalciferol[81]. Cholecalciferol comes from animals and people through the biosynthesis of cholesterol to 7-dehydrocholesterol (Provitamin D3). Again, through UVB irradiation, this intermediate becomes cholecalciferol. Thus, dietary intake and sun exposure are the major determinants of serum 25-hydroxyvitamin D levels.

Sun, mainly UVB irradiation, plays an important role in biosynthesis of vitamin D. Since 7-dehydrocholesterol can be synthesized from cholesterol, theoretically vitamin D supplementation is not required once sun exposure is adequate. Skin color is a key determinant of vitamin D synthesis[82]. Vitamin D has been proposed to play a role in human evolution and migration away from equator by affecting skin color through the development of depigmented and tannable skin *via* genetic pathways under positive selection[1,83]. Sun exposure is highly effective in raising serum 25-hydroxyvitamin D concentration, while its effects diminish significantly on donning clothing and using sun screen[84]. In this regard, more body surface area exposure is more effective than longer exposure time[85]. However, the efficacy of sun exposure to increase serum 25-hydroxyvotamin D concentrations diminishes with the degree of skin tanning[86]. Thus, minimized sun exposure time for 5 min to 30 min (depending on time of day, season, latitude, and skin pigmentation) with maximize body surface exposure is recommended[9]. However, increased risk of sun-mediated skin cancer makes this approach to prevent vitamin D deficiency less optimum[87].

Vitamin D can be obtained through dietary intake. However, except for cod liver oil, vitamin D content in naturally occurring food is relatively low, even in mushrooms (Table 2). Although ergosterol is highly abundant in the membrane of mushrooms, mushroom are cultivated under shadow without UVB irradiation[81]. Thus, dietary intake of vitamin D is inadequate and vitamin D supplement is often needed to avoid deficiency.

***Comparison of metabolism of vitamin D2 vs vitamin D3***

It is estimated that 65% of vitamin D is present as vitamin D while 35% is in the form of 25-hydroxyvitaomn D. As well, almost 75% of vitamin D is in adipose tissue, while 25-hydroxyvitamin D is distributed 20% in muscle, 30% in serum, 35% in fat, and 15% in other tissues[88]. The metabolism of vitamin D3 and vitamin D2 is summarized in Table 3. Vitamin D binding protein transports the various forms of vitamin D in circulation, including vitamin D, 25-hydroxyvtamin D, and 1,25-dihydroxyvitamin D[89]. Each vitamin D binding protein molecule has one binding site for vitamin D and/or its metabolites. The relative affinity of vitamin D binding protein to vitamin D3 is 1.14 times stronger than to vitamin D2[90]. 25-hydroxylase (CYP2R1) catalyzes 25-hydroxylation of vitamin D3 5 times more efficiently than vitamin D2[91]. Thus, after administration of a single oral dose of vitamin D3 and vitamin D2, a more sustainable and prolonged increase in serum 25-hydroxybitamin D3 concentration is observed compared to serum 25-hydroxybitamin D2 concentration[92]. 1alpha-hydroxylase (CYP27B1) coverts 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 2.4-time more efficiently than 25-hydroxyvitamin D2[93]. In receptor binding assays, 1,25-dihydroxyviramin D3 has 1.3 times more receptor affinity than 1,25-dihdroxyvitamin D3[94]. These data indicate that vitamin D3 is more biologically potent than vitamin D2.

***Comparison of biological potency of vitamin D2 vs vitamin D3***

Vitamin D2 and vitamin D3 were reported to have similar efficacy in raising serum 25-hydroxyviramin D concentration[95]. However, other studies demonstrated that vitamin D3 was more efficacious at raising serum 25(OH)D concentrations than vitamin D2[96-100]. This finding was confirmed by a meta-analysis of the randomized control trials[101]. Furthermore, 25-hydroxyvitamin D3 has a longer half-life compared to 25-hydroxyvitamin D2 (15.1 ± 3.1 d *vs* 13.9 ± 2.6 d, *P* = 0.001, mean ± STD)[18]. In comparison to oral vitamin D2, oral vitamin D3 achieves a higher serum concentration of 1,25-dihydroxyvitamin D[100,102] and a more effective suppression of serum parathyroid hormone concentration[97]. Physicians preferring use of vitamin D2 should be aware of its markedly lower potency and shorter duration of action when compared to vitamin D3. Thus, vitamin D3 is the preferred form of vitamin D for replacement therapy.

**Optimal serum 25-hydroxyvitamin D concentration**

***Minimal serum 25-hydroxyvitamin D concentration***

The primary function of vitamin D is to maintain calcium homeostasis. The minimal serum 25-hydroxyvitamin D concentration for health was defined based on the serum parathyroid hormone response to replacement therapy with ergocalciferol[103]. A serum 25-hydroxyvitamin D concentration of 50 nmol/L (20 ng/mL) was recommended since no further changes in serum parathyroid hormone levels were found in subjects with a serum 25-hydroxyvitamin D level of 50 nmol/L (≥ 20 ng/mL). In 2010, the United Sates Institute of Medicine adapted this value as a target for ensuring good bone health[104]. However, based on a larger observational study with 1569 subjects in France, serum parathyroid hormone concentration were noted to still decrease when the serum 25-hydroxyvitamin D rose to 78 mmol/L (31 ng/mL)[105]. Furthermore, a serum 25-hydroxyvitamin level of 75 nmol/L (30 ng/mL) is a recognized threshold for intestinal calcium absorption[106]. As shown in Table 4, many professional organizations and agencies have since adapted 75 nmol/L (30 ng/mL) as the minimal acceptable serum 25-hydroxyvitamin D concentration recognizing this may have beneficial effects beyond bone health, targeting beyond bone health while the Institute of Medicine define the minimal 25-hydroxyvitamin D concentration 50 nmol/L (20 ng/mL) on bone health with a public health interest.

***Maximal serum 25-hydroxyvitamin D concentration***

The maximal allowed serum 25-hydroxyvitamin D concentration is defined by the appearance of adverse effects. Although the Institute of Medicine dose not define maximal serum 25-hydroxyvitamin D concentration[104], a warning against elevated serum 25-hydroxyvitamin D concentrations is stated. This warning is based upon the observed association of increasing mortality with serum 25-hydroxyvitamin D concentration > 125 nmol/L (50 ng/mL)[107] by limiting the maximal daily vitamin D allowance (Table 4). This notion was further supported by the finding of increased cardiovascular mortality with serum 25-hydroxyvitaminD > 125 nmol/L (50 ng/mL)[108]. In addition, a progressive decline in bone mineral density with serum 25-hydroxyvitamin D greater than 125 nmol/L (50 ng/mL) was observed in a United States population[109]. Conversely, bone mineral density improved after discontinuation of vitamin D supplementation in patients with a serum 25-hydroxyvitamin D concentration greater than 50 ng/mL[110]. Although vitamin D supplementation increased calcium absorption without a threshold effect[111], reanalysis of the data revealed a diminished response (per 1000 IU of vitamin D in Table 5) with increasing dose of vitamin D supplement suggesting a threshold effect of vitamin D on calcium absorption[112], something noted by others[106]. We reported lack of improvement in insulin sensitivity in individuals with a serum 25-hydroxyvitamin D concentration > 125 nmol/L (50 ng/mL)[113]. Although hypercalcemia from vitamin D intoxication occurs mainly when the serum 25-hydroxyvitamin D concentration is > 374 nmol/L (150 ng/mL)[114], serum 25-hydroxyvitamin D concentrations > 75 nmol/L (50 ng/mL) could be either harmful or lack beneficial effect.

***Comparison of daily replacement vs intermittent replacement of vitamin D***

The observation that a single oral dose of vitamin D3 2.5 mg (100000 IU) can maintain serum 25-hydroxyvitamin D above the target goal[115] provides a unique dosing strategy of vitamin D replacement therapy with greater adherence. It could even ensure 100% compliance if given by or under the direct supervision of a health care provider. Weekly[103], monthly[116], biyearly[117], and even yearly[118] schedules were reported in various trials leading to initiation of more convenient dosing schedule at less frequent intervals in clinical practice. To reduce the dosing frequency, a much higher dose of vitamin D is required which is predicted to cause a short-term spike (> 75 nmol/L or 50 ng/mL) in serum 25-hydroxyvitamin D concentration shortly after oral administration. In addition to the adverse effects as described in the above section 4.2, increased falls and fracture are observed with annual vitamin D replacement therapy. These mainly occur within the first 3 mo after oral administration of 12.5 mg vitamin D3[118]. Furthermore, the associations of high-dose vitamin D treatment with gastrointestinal complaints[119], increased bone turnover markers[120], hypercalcemia[121], hypercalciuria[122], and increased urinary magnesium loss[123] have been reported. Similar levels of serum 25-hydroxyvitamin D concentration were achieved at the end of a 56-d trial from daily (1500 IU/d), weekly (10500 IU/wk), and monthly (45000 IU/4 wk) replacement therapy. Excessive serum 25-hydroxyvitamin D concentration was not observed in those on the daily regimen but was observed in individuals on the weekly regimen and was still more common in those on monthly regimen[124]. Thus, high-dose vitamin D replacement therapy results in excessive serum 25-hydroxyvitamin D concentration.

A Lysine (K) amino acid polymorphism, in replacement of Threonine (T), at position 436 of vitamin D binding protein is associated with increased affinity of vitamin D and is associated a 416% elevation in serum 25-hydroxyvitamin D concentration if high-dose (4000 IU) vitamin D3 replacement therapy if given as opposed to low-dose (600 IU) vitamin D3 replacement therapy. Individuals carrying the TT SNP showed only a 136% increase in circulating vitamin[125]. Since the K allele is a minor allele and KK genotype accounts for less than few percent of population, the KK subjects may account for the excessive serum 25-hydroxyvitamin D-associated complications noted in certain studies. Given the above, daily vitamin D supplementation would seem to be most physiological and safest way to correct vitamin D deficiency and avoid the possible adverse effects associated with the excessive serum 25-hydroxyvitamin D concentration.

***Factors affecting serum 25-hydroxyvitamin D concentration***

Various genetic loci are associated with serum 25-hydroxyvitamin D concentration[126] with 4 major loci identified (Table 6). These are all key proteins involved in the transportation and metabolism of vitamin D. Race and ethnicity were noted to have significant impact on serum 25-dihyrdroxyvitamin D concentration[127], again implicating a genetic influence[126] including skin color[128].

Seasonable variations in serum 25-hydroxyvitanim D concentrations related to sun exposure are well described[126]. Consistent with this, latitude has a significant impact on serum 25-dihydrocyvitamin D concentration[129]. Living closer to the equator and increasing sun exposure can improve vitamin D levels. However, the increased risk of skin cancer from sun exposure should be balanced employing maximum skin exposure area with decreased exposure time[85]. Dietary supplementation also corrects deficiency. Obesity is associated with a lower serum 25-hydroxyvitamin D concentration[72] while weight reduction with loss of adipose tissue is associated with improvement in serum 25-hydroxyvitamin D concentration[130]. These findings indicate that vitamin D status may be improved through modification of lifestyle.

***Practical recommendations for vitamin D replacement therapy***

As showed in Table 4, the recommended vitamin D supplement varies between organizations and agencies. The reasons for this relate to the purpose of vitamin D supplementation, visive calcemic *vs* non-calcemic effects. For calcemic effects, bone health is the goal of supplementation and is maximized through using a conservative daily vitamin D to achieve the minimal serum 25-hydroxyvitamin D concentration while avoiding possible adverse effects associated with overreplacement. A public health approach to this is displayed in Table 7. In contrast, a more personized approach is rationale when the target is to promote the non-calcemic effects of vitamin D.

We recommend using vitamin D3, instead of vitamin D2, for the rationale as discussed in the sections 3.2 and 3.3. We are in favor of daily replacement therapy and against intermittent mega dose replacement. This is supported by the recommendations of the Endocrine Society for indefinitely intermittent mega dose replacement[131]. It has been estimated that supplement with cholecalciferol 1000 IU (50 μg) daily will increase serum 25-hydroxyvitamin D concentration by 10 ng/mL[132]. Since vitamin D is a fat soluble, replacement therapy can be further enhanced by taking it with the largest meal of day[133]. We recommend vitamin D3 1000 IU daily for achievement of an initial serum 25-hydroxyvitamin D concentration between 51 nmol/L (21) ng/mL and 75 nmol/L (30 ng/mL); 2000 IU daily for between 26 nmol/L (11 ng/mL) and 50 nmol/L (20 ng/mL); and 5000 IU for equal or less than 25 nmol/L (10 ng/mL). Serum 25-hydroxyvitamin concentration should be measured within 3 mo for assessment and, if indicated, dose adjustment. We are targeting serum 25-hydroxyvitamin D concentration between 75 nmol/L (30 ng/mL) and 125 nmol/L (50 ng/mL).

**Vitamin D and diabetes prevention**

***Vitamin D diabetes prevention trials***

To date, eight clinical trials employed vitamin D to reduce prediabetes progression to overt diabetes (Table 8). Only two studies[134,135] demonstrated positive results. Although these two studies had small sample size, they recruited true vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L or 20 ng/mL) subjects and achieved final 25-hydroxyvitamin D concentration at 89-90 nmol/L, after intervention for 1 year and 6 mo, respectively. Of note, the study in India[134] was a randomized open label study demonstrating an odds ratio of 0.31 [95% confidence intervals (CI): 0.11-0.90]. The study in Iran was a randomized placebo control study[135] revealing an odds ratio of 0.06 (95%CI: 0.01-0.51). Because of relatively small sample sizes of both studies, the CI were very wide. Additional studies with similar initial and final 25-hydroxyvitamin D concentration (< 50 nmol/L and 90-100 nmol/L, respectively) and much larger sample sizes are required to confirm these data.

Two negative studies[136,137] were noted to have similar initial 25-hydroxyvitamin D concentrations (25-42 nmol/L). The negative results could be due to the relatively short interventions (8-16 wk) and small sample sizes. The study in Holland only achieved a final suboptimal 25-hydroxyvitamin D concentration of 60 nmol/L.

The other four studies[138-141] had a final 25-hydroxyvitamin D concentration > 100 nmol/L which might not be optimal for glucose metabolism. Among them, the study in African American[141] was the only study that recruited true vitamin D deficient subjects (initial 25-hydroxyvitamin D 37 nmol/L). Of note, ergocalciferol was used which could be less effective biologically as discussed above in 3.2 and 3.3. Enrollment of non-vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L) subjects[138-140] could further reduce the chance of finding any effect. Furthermore, the study in Norway had a significant dropout rate in the interventional group with only 45% of participants completing the planned 5-year visit. The largest intervention trial[138] included more than 1000 subjects in each group. To be able to apply to the general population in the United States, this study did not target vitamin D deficient subjects and allowed the participants to take additional vitamin D up to 25 μg daily. Therefore, it had the highest initial 25-hydroxyvitamin D among these studies, 70 nmol/L in the control group and 69 nmol/L in the interventional group, which might diminish the power of this study to detect the beneficial effect of vitamin D. Regardless of the negative results in most studies, the beneficial effect of vitamin D supplementation cannot be completely excluded, especially in subjects with vitamin D deficiency (25-hydroxyvitamin D < 50 nmol/L).

***The effects of vitamin D supplement on parameters of glucose metabolism***

Various parameters of glucose metabolism were reported in most of above-mentioned studies, except one[138]. After vitamin D intervention for 1 year, the study from India[134] observed improvement in fasting and 2-hr post-challenge glucose concentrations, insulin sensitivity by Homeostasis Model (HOMA) insulin resistance index, QUICKI, and 1/fasting insulin concentration while no impact on HbA1c and beta cell function by HOMA. Following vitamin D supplement for 6 mo, the study from Iran[135] reported the improvement in the HOMA insulin resistance index and marginal improvement in fasting insulin concentration (*P* = 0.05) and 2-hour post-challenge blood glucose concentration (*P* = 0.07) with no impact on fasting blood glucose concentration.

After an 8-wk intervention, the study from Sweden[136] assessed insulin sensitivity and beta cell function using the hyperglycemic clamp. They observed a significant improvement in deposition index based on the first phase insulin response (*P* = 0.005) and marginal improvement in first phase insulin response (*P* = 0.06), insulin sensitive index (*P* = 0.09), deposition index based on the second phase insulin response (*P* = 0.06), and A1c (*P* = 0.06) but no impact on the second phase insulin response and fasting and 2-hr post-challenge blood glucose concentration.

In contrast, the study from Holland[137] evaluated glucose metabolism parameters based on the 75-g glucose tolerance test following intervention for 16 wk. They reported negative results, finding no effects upon insulin area under curve, glucose area under curve, insulin sensitivity by composite insulin sensitivity index, Stumvoll index, insulin resistance index by HOMA, and beta cell function by insulinogenic index. Of note, the final 25-hydroxyvitamin D concentration was only 60 nmol/L which could be suboptimal for glucose metabolism. Similarly, after the vitamin D supplementation for 5 years, the study from Norway[140] observed no impact on fasting and 2-hr post-challenge serum glucose concentration, fasting and post challenge serum insulin concentration, fasting serum C-peptide concentration, HbA1c, and insulin sensitivity by HOMA insulin resistance index and QUICKI.

Following a 12-mo intervention, the study involving Latino and African Americans[139] observed a significant improvement in HbA1c but no effects on fasting and 2-hr post-challenge blood glucose concentration, beta cell function by the ratio of insulin and glucose area under curve, Stumvoll first and second insulin response, insulinogenic index, insulin sensitivity index by HOMA insulin resistance index and composite insulin sensitivity index, and oral disposition index. However, a significant improvement in composite insulin sensitivity index but not Matsuda index, insulinogenic index, C-peptidogenic index, and HbA1c was noted.

Excepting two studies[137,140] with negative results, favorable outcomes on parameters of glucose metabolism were reported in five studies[134-136,139,141] suggesting some benefits to supplementation under these conditions.

***Summary of vitamin D and diabetes prevention***

In vitamin D deficient (25-hydroxyvitamin D < 50 nmol/L) prediabetic subjects, vitamin D supplement appears to be effective in reduction of the development of overt diabetes. However, there appears to be no benefit in vitamin D sufficient subjects, which was noted in a study from Norway[142]. Based on pooled data from four intervention trials, in subjects without vitamin D deficiency there is no improvement in glucose metabolism with high dose vitamin D supplementation and if anything, the effect is negative[143]. This notion is consistent with the observed threshold effect of vitamin D on bone health and lack of benefit in subjects with baseline 25-hydroxyvitamin D level ≥ 75 nmol/L (30 ng/mL)[14,15].

**Laboratory evidence supporting the effect of vitamin D on glucose and fuel homeostasis**

***Beta cell function***

**Functional beta cell studies:** The important role of vitamin D on insulin secretion has been noted in laboratory animals since 1980. Insulin secretion was reduced by about 50% in isolated perfused islets from vitamin D-deficient rats compared to controls[144]. Interestingly, 1,25-dihydroxyvitamin D3 was noted in cell nuclei in the islets of langerhans[145]. Furthermore, administration of 1,25-dihydroxyvitamin D3 to vitamin D-deficient rats improved insulin secretion significantly when compared to controls[146]. Vitamin D deficiency impaired both phases of insulin release in rats while correction of hypocalcemia failed to reverse the defect in insulin release[147]. Vitamin D, but not calcium, was essential for normal insulin secretion from the perfused rat pancreas[148]. The positive effect of single dose of 1,25-dihydroxyvitamin D3 on insulin secretion was apparent at 8 h in perfused rat pancreata, peaked at 14 h, and then decreased to pretreatment baseline values by 36 h[149]. Dietary vitamin D3 supplementation improved impaired glucose tolerance and insulin secretion in the vitamin D-deficient rats[150]. A dose-dependent effect from parenteral 1,25-dihydroxyvitamin D on insulin secretion and glucose metabolism was observed within 3 h and remained effective up to 20 h in the vitamin D-deficient rats[151]. The role of vitamin D on insulin synthesis and secretion was supported by studies in vitamin D receptor knockout mice. Insulin secretory capacity was reduced by 60% in vitamin D receptor knockout mice[152] with increased post-challenged blood glucose but normal fasting blood glucose concentration and reduced insulin mRNA levels in pancreatic islets but normal pancreatic beta cell mass, islet architecture, and islet neogenesis when compared to wild type mice. Thus, vitamin D plays an important role in pancreatic insulin synthesis and secretion in vivo.

**Mechanistic studies of beta cell function:** Although the essential role of vitamin D on insulin secretion has been established in vitamin D depleted laboratory animal, details of the underlying molecular mechanism remain to be defined. Employing a proteomic approach, treatment with 1,25-dihydroxyvitamin D3 resulted in 31 differentially expressed proteins in INS-1 beta-like cells[153] with 29 upregulated, some of which were implicated in insulin granule motility and insulin exocytosis as well as regulation of ions. Pretreatment of INS1E cells with 1,25-dihydroxyvitamin D or 25-hydroxyvitamin D and glucose resulted in 526 and 181 differentially expressed genes, respectively[154].

Several molecular mechanisms were proposed to account for the effects of vitamin D on beta cells, including changes in the local pancreatic islet renin-angiotensin system[155], restoration of GLUT2 expression[156], enhancement of IP3 and AMPA receptor expression[157], vitamin D-binding protein-induced beta cell dedifferentiation[158], reduction of oxidative damage[159], reduced cholinergic pancreatic effects[160], enhanced transcriptional regulation of voltage-gated calcium channels[161], and elevation of PPAR-γ expression[162]. However, further studies are required to confirm the proposed mechanisms.

***Insulin sensitivity***

**Functional studies of insulin sensitivity:** In contrast to beta cell function, there are fewer studies of insulin sensitivity. Dietary supplementation of vitamin D improved insulin sensitivity, hepatic steatosis, and myocardial fibrosis in Western diet fed rats[163]. In dietary-induced obese mice, vitamin D receptor activation in liver macrophages improved insulin sensitivity with reduction of hepatic inflammation and steatosis[164]. Vitamin D treatment improved insulin resistance index in a nongenetic model of type 2 diabetes[165]. However, vitamin D status were not reported in these studies.

**Mechanistic studies of insulin sensitivity:** Chronic central administration of 1,25-dihydroxyvitamin D3 dramatically reduced body weight, putatively by lowering food intake, in obese rodents[166]. Treatment with vitamin D increased mitochondrial function and insulin sensitivity, in part, through upregulation of perilipin 2, a perilipin protein upregulated with 1,25-dihydroxyvitamin D treatment[167]. In skeletal myocytes, vitamin D reduced insulin resistance by altering lipid partitioning and lipid droplet packaging in favor of lipid turnover[168]. FGF-23 knockout mice are hypoglycemic with profoundly increased peripheral insulin sensitivity and improved subcutaneous glucose tolerance. Ablation of vitamin D signaling in these mice normalized subcutaneous glucose tolerance tests and insulin sensitivity[169]. Caveolin-1 protein, which is necessary for vitamin D signaling, could play a role in vitamin D-induced insulin sensitivity in skeletal muscle[170]. In cultured rat osteoblasts, 1,25-dihydroxyvitamin D3 treatment increased expression of the insulin and vitamin D receptors, and elevated osteocalcin levels under high glucose exposure[171], which may in turn improve insulin sensitivity.

However, the results of vitamin D receptor knockout mice were less uniform. Skeletal muscle-specific vitamin D receptor knockout mice developed insulin resistance and glucose intolerance accompanied by increased expression and activity of FOXO1[172]. Deletion of macrophage vitamin D receptor promoted insulin resistance and monocyte cholesterol transport and accelerated atherosclerosis[173]. In contrast, deletion of the vitamin D receptor gene in endothelial cells improved glucose tolerance and insulin sensitivity in skeletal muscle and reduced expression and secretion of insulin in pancreatic islets[174]. Together these data indicate that vitamin D has positive and negative effects on insulin sensitivity that are cell and organ specific.

**Concerns arising with reported studies**

***Lack of true vitamin D deficient subjects***

Due to publicity and potential non-calcemic benefits of vitamin D supplementation, the sale of vitamin D supplements increased significantly and taking vitamin D supplements is common. Thus, there are less true vitamin D deficient subjects available for inclusion in clinical trials. As well, a general lack of funding support for large trials impedes addressing the ability of researchers to address the gaps in knowledge surrounding vitamin D and its beneficial effects.

***Lack of beneficial effects from suboptimal replacement and detrimental effects of over-replacement***

To obtain the maximal effect of vitamin D, serum 25-hydroxyvitamin D concentration should be maintained in an optimal range, namely between 75 nmol/L (30 ng/mL) and 125 nmol/L (50 ng/mL). Inadequate vitamin D replacement therapy will reduce the chance to observe the expected beneficial effect of vitamin D while adverse effects associated with excessive serum 25-hydroxyvtamin D concentration will also cloud data interpretation. Although mega doses of vitamin D given intermittently could improve compliance in a study protocol, the predicted wide swings in serum 25-hydroxyvitamin D concentrations will confound outcomes. It is important in clinical studies to use a proper daily dose to avoid these pitfalls.

***Inadequate sample size***

The Diabetes Prevention Program demonstrated a 58% (95%CI: 48%-66%) reduction in the incidence of diabetes in the lifestyle intervention group (cumulative incidence of diabetes 14.4% in 1079 participants) and a 31% reduction in diabetes (95%CI: 17%-43%) in the metformin treated group (cumulative incidence of diabetes 21.7% in 1073 participants) when compared to the placebo (cumulative incidence of diabetes 28.9% in 1082 participants)[175]. Insulin sensitivity improved by 61.8% in the lifestyle intervention group and 28.3% in the metformin group[176]. This study can be employed to calculate a sample size sufficient for assessing the effects of vitamin D intervention.

Based on the non-linear relationship of serum 25-hydroxyvotamin D concentration and insulin sensitivity index as we reported[113], we constructed Table 9. Assuming a linear relationship between improvement in insulin sensitivity and reduction of diabetes from the Diabetes Prevention Program[175,176], we calculated the required sample size to detect the reduction of diabetes incidence after vitamin D replacement therapy in a population similar to that of the Diabetes Prevention Program[175] with a power of 0.80 to detect the proposed difference and a type I error rate, alpha, of 0.05 in a clinical trial of 3 years. Starting with a baseline serum 25-hydroxyviyamin D of 25 ng/mL (10 ng/mL), 170 subjects would be needed. Such a study cohort size is not excessive. However, if the baseline serum 25-hydroxyvitamin D is equal or greater than 50 nmol/L (20 ng/mL) the cohort size needed increases markedly. These calculations suggest that all studies to date are flawed secondary to inadequate sample size.

It has been frustrating to confound the published negative reports while ample evidence supports the benefit of vitamin D. Accordingly, we propose these guidelines[177]. Future studies into the effects of vitamin D supplementation need to ensure the proper selection of study subjects, adequate vitamin D replacement to achieve an optimal serum 25-hydroxyvitamin D concentrations, avoidance over-placement to eliminate detrimental effects, and adequate sample size to detect the proposed effects.

**The issues that need to be addressed by the future studies**

***Optimal serum 25-hydroxyvitamin D concentration for glucose metabolism***

Table 4 summarizes the recommended serum vitamin D concentrations from several institutions and agencies. As appreciated, studies on bone health[14,15] showed no additional benefit in the subjects with serum 25-hydroxyvitmanin D > 75 nmol/L (30 ng/mL) and this agrees with the effects upon diabetes prevention. However, increased all-cause mortality[107] and cardiovascular mortality[108] occurred prior to the 125 nmol/L (50 ng/mL) threshold, implying a much lower maximum dose for optimal serum 25-hydroxyvitamin D concentration. The question remains whether the same relationship applies to glucose homeostasis.

***Detrimental effects on glucose metabolism for serum 25-hydroxyvitamin D concentrations above a maximum threshold***

The detrimental effects noted in individuals with serum 25-hydroxyvitamin D concentration above a maximum threshold was observed in a cross-sectional study[109]. Further, improvement in bone density after discontinuation of vitamin D supplementation in osteoporotic patients with elevated serum 25-hydroxyvitamin D concentration was reported[110]. Elevated serum 25-hydroxyvitamin D concentrations were also associated with increased falls and fracture[118]. These reports suggest that assessment of negative effects from elevated serum 25-hydroxyvitamin D concentration may be uncovered with additional study.

***Diabetes prevention in vitamin D deficit subjects***

Although various evidence suggests the benefit of vitamin D on glucose metabolism, published diabetes prevention trails are not convincing and suffer from improper designed and execution. To address this issue, a well-designed and well-conducted randomized, placebo-control trial to test the effects of vitamin D to limit development of diabetes is warranted, by selecting true vitamin D deficient subjects, achieving optimal but not excessive serum 25-hydroxyvitamin concentration, and enrolling adequate number of subjects. Properly monitoring serum 25-hydroxyvitamin D concentrations is required during the study.

**CONCLUSION**

The role of vitamin D in glucose metabolism and fuel homeostasis is supported by a number of observational studies. We reported that serum 25-hydroxyviatmin D concentration accounted for 21.2% of the variation in insulin sensitivity index in univariate analysis and 6.1% by itself among 42% with other covariates in multivariate analysis[178]. We also reported that serum 25-hydroxyviatmin D concentration accounted for 8.2% of the variation in beta cell function in univariate analysis and 4.5% by itself among 25.5% with other covariates in multivariate analysis[179]. Although the intervention studies have failed to provide concordant data for multiple reasons, laboratory studies revealed a number of molecular mechanisms that underlie the effect of vitamin D supporting the important role of the vitamin in glucose metabolism and fuel homeostasis. Since the independent contributions of vitamin D to insulin sensitivity[178] and beta cell function[179] are relatively small, vitamin D deficiency could be the last straw that breaks camel’s back in polygenetic and multifactorial diseases, such as diabetes, obesity, and hyperlipidemia.

**ACKNOWLEDGEMENTS**

A special acknowledgement is due to Chiu-Tien Chiu, MD, PhD for his unconditional support to KCC. We are in debt to Jeffrey Isenberg MD, MPH for critical reading and editing of the manuscript.

**REFERENCES**

1 **Diamond J**. Evolutionary biology: geography and skin colour. *Nature* 2005; **435**: 283-284 [PMID: 15902239 DOI: 10.1038/435283a]

2 **Platt BS**. Sir Edward Mellanby, G.B.E., K.C.B., F.R.S. *Nature* 1955; **175**: 530-532 [PMID: 14370159 DOI: 10.1038/175530a0]

3 **McCollum EV**, Pitz W, Simmonds N, Becker JE, Shipley PG, Bunting RW. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. Studies on experimental rickets. XXI. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. 1922. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. *J Biol Chem* 2002; **277**: E8 [PMID: 11991957]

4 **Deluca HF**. History of the discovery of vitamin D and its active metabolites. *Bonekey Rep* 2014; **3**: 479 [PMID: 24466410 DOI: 10.1038/bonekey.2013.213]

5 **Askew FA**, Bourdillon RB, Webster TA. The production of vitamin D in a glow discharge. *Biochem J* 1932; **26**: 814 [PMID: 16744889 DOI: 10.1042/bj0260814]

6 **DeLuca HF**. Current concepts. Vitamin D. *N Engl J Med* 1969; **281**: 1103-1104 [PMID: 4309963 DOI: 10.1056/NEJM196911132812006]

7 **Holick MF**. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. *Bone* 1995; **17**: 107S-111S [PMID: 8579891 DOI: 10.1016/8756-3282(95)00195-j]

8 **Mitchell F**. Vitamin-D and COVID-19: do deficient risk a poorer outcome? *Lancet Diabetes Endocrinol* 2020; **8**: 570 [PMID: 32445630 DOI: 10.1016/S2213-8587(20)30183-2]

9 **Holick MF**. Vitamin D deficiency. *N Engl J Med* 2007; **357**: 266-281 [PMID: 17634462 DOI: 10.1056/NEJMra070553]

10 **Aloia J**, Fazzari M, Islam S, Mikhail M, Shieh A, Katumuluwa S, Dhaliwal R, Stolberg A, Usera G, Ragolia L. Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial. *J Bone Miner Res* 2018; **33**: 1916-1922 [PMID: 29905969 DOI: 10.1002/jbmr.3521]

11 **Aspray TJ**, Chadwick T, Francis RM, McColl E, Stamp E, Prentice A, von Wilamowitz-Moellendorff A, Schoenmakers I. Randomized controlled trial of vitamin D supplementation in older people to optimize bone health. *Am J Clin Nutr* 2019; **109**: 207-217 [PMID: 30624670 DOI: 10.1093/ajcn/nqy280]

12 **Burt LA**, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial. *JAMA* 2019; **322**: 736-745 [PMID: 31454046 DOI: 10.1001/jama.2019.11889]

13 **Reid IR**, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. *Lancet* 2014; **383**: 146-155 [PMID: 24119980 DOI: 10.1016/S0140-6736(13)61647-5]

14 **Reid IR**, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M, Taylor L, Fenwick S, Camargo CA, Stewart AW, Scragg R. Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. *J Intern Med* 2017; **282**: 452-460 [PMID: 28692172 DOI: 10.1111/joim.12651]

15 **Macdonald HM**, Reid IR, Gamble GD, Fraser WD, Tang JC, Wood AD. 25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial. *J Bone Miner Res* 2018; **33**: 1464-1469 [PMID: 29665087 DOI: 10.1002/jbmr.3442]

16 **Glossmann HH**. Origin of 7-dehydrocholesterol (provitamin D) in the skin. *J Invest Dermatol* 2010; **130**: 2139-2141 [PMID: 20445550 DOI: 10.1038/jid.2010.118]

17 **Nicoloff JT**, Low JC, Dussault JH, Fisher DA. Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. *J Clin Invest* 1972; **51**: 473-483 [PMID: 4110897 DOI: 10.1172/jci106835]

18 **Jones KS**, Assar S, Harnpanich D, Bouillon R, Lambrechts D, Prentice A, Schoenmakers I. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. *J Clin Endocrinol Metab* 2014; **99**: 3373-3381 [PMID: 24885631 DOI: 10.1210/jc.2014-1714]

19 **Berry D**, Hyppönen E. Determinants of vitamin D status: focus on genetic variations. *Curr Opin Nephrol Hypertens* 2011; **20**: 331-336 [PMID: 21654390 DOI: 10.1097/MNH.0b013e328346d6ba]

20 **Fagerberg L**, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics* 2014; **13**: 397-406 [PMID: 24309898 DOI: 10.1074/mcp.M113.035600]

21 **Lee S**, Clark SA, Gill RK, Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. *Endocrinology* 1994; **134**: 1602-1610 [PMID: 8137721 DOI: 10.1210/endo.134.4.8137721]

22 **Zhang H**, Shen Z, Lin Y, Zhang J, Zhang Y, Liu P, Zeng H, Yu M, Chen X, Ning L, Mao X, Cen L, Yu C, Xu C. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. *J Biol Chem* 2020; **295**: 3891-3905 [PMID: 32051143 DOI: 10.1074/jbc.RA119.011487]

23 **Bischoff-Ferrari HA**, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. *J Bone Miner Res* 2004; **19**: 265-269 [PMID: 14969396 DOI: 10.1359/jbmr.2004.19.2.265]

24 **Yuzbashian E**, Asghari G, Hedayati M, Zarkesh M, Mirmiran P, Khalaj A. Determinants of vitamin D receptor gene expression in visceral and subcutaneous adipose tissue in non-obese, obese, and morbidly obese subjects. *J Steroid Biochem Mol Biol* 2019; **187**: 82-87 [PMID: 30412764 DOI: 10.1016/j.jsbmb.2018.11.004]

25 **Bland R**, Markovic D, Hills CE, Hughes SV, Chan SL, Squires PE, Hewison M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. *J Steroid Biochem Mol Biol* 2004; **89-90**: 121-125 [PMID: 15225758 DOI: 10.1016/j.jsbmb.2004.03.115]

26 **Vuica A**, Ferhatović Hamzić L, Vukojević K, Jerić M, Puljak L, Grković I, Filipović N. Aging and a long-term diabetes mellitus increase expression of 1 α-hydroxylase and vitamin D receptors in the rat liver. *Exp Gerontol* 2015; **72**: 167-176 [PMID: 26471398 DOI: 10.1016/j.exger.2015.10.005]

27 **Srikuea R**, Zhang X, Park-Sarge OK, Esser KA. VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation. *Am J Physiol Cell Physiol* 2012; **303**: C396-C405 [PMID: 22648952 DOI: 10.1152/ajpcell.00014.2012]

28 **Wamberg L**, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L, Richelsen B, Pedersen SB. Expression of vitamin D-metabolizing enzymes in human adipose tissue -- the effect of obesity and diet-induced weight loss. *Int J Obes (Lond)* 2013; **37**: 651-657 [PMID: 22828938 DOI: 10.1038/ijo.2012.112]

29 **Hewison M**, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. *J Mol Endocrinol* 2000; **25**: 141-148 [PMID: 11013342 DOI: 10.1677/jme.0.0250141]

30 **Garland CF**, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? *Int J Epidemiol* 1980; **9**: 227-231 [PMID: 7440046 DOI: 10.1093/ije/9.3.227]

31 **Garland FC**, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. *Prev Med* 1990; **19**: 614-622 [PMID: 2263572 DOI: 10.1016/0091-7435(90)90058-r]

32 **Ahonen MH**, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control* 2000; **11**: 847-852 [PMID: 11075874 DOI: 10.1023/a:1008923802001]

33 **Garland CF**, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. *Lancet* 1989; **2**: 1176-1178 [PMID: 2572900 DOI: 10.1016/s0140-6736(89)91789-3]

34 **Abe E**, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. *Proc Natl Acad Sci U S A* 1981; **78**: 4990-4994 [PMID: 6946446 DOI: 10.1073/pnas.78.8.4990]

35 **Peehl DM**, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. *Cancer Res* 1994; **54**: 805-810 [PMID: 7508338]

36 **Masuda S**, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. *Mol Cancer Ther* 2006; **5**: 797-808 [PMID: 16648549 DOI: 10.1158/1535-7163.MCT-05-0539]

37 **Samuel S**, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. *Nutr Rev* 2008; **66**: S116-S124 [PMID: 18844838 DOI: 10.1111/j.1753-4887.2008.00094.x]

38 **Hyppönen E**, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet* 2001; **358**: 1500-1503 [PMID: 11705562 DOI: 10.1016/S0140-6736(01)06580-1]

39 **Chang TJ**, Lei HH, Yeh JI, Chiu KC, Lee KC, Chen MC, Tai TY, Chuang LM. Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population. *Clin Endocrinol (Oxf)* 2000; **52**: 575-580 [PMID: 10792336 DOI: 10.1046/j.1365-2265.2000.00985.x]

40 **Zella JB**, DeLuca HF. Vitamin D and autoimmune diabetes. *J Cell Biochem* 2003; **88**: 216-222 [PMID: 12520517 DOI: 10.1002/jcb.10347]

41 **Munger KL**, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A. Vitamin D intake and incidence of multiple sclerosis. *Neurology* 2004; **62**: 60-65 [PMID: 14718698 DOI: 10.1212/01.wnl.0000101723.79681.38]

42 **Kamen DL**, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev* 2006; **5**: 114-117 [PMID: 16431339 DOI: 10.1016/j.autrev.2005.05.009]

43 **Maruotti N**, Cantatore FP. Vitamin D and the immune system. *J Rheumatol* 2010; **37**: 491-495 [PMID: 20080911 DOI: 10.3899/jrheum.090797]

44 **Murdaca G**, Tonacci A, Negrini S, Greco M, Borro M, Puppo F, Gangemi S. Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. *Autoimmun Rev* 2019; **18**: 102350 [PMID: 31323357 DOI: 10.1016/j.autrev.2019.102350]

45 **Chen S**, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J Immunol* 2007; **179**: 1634-1647 [PMID: 17641030 DOI: 10.4049/jimmunol.179.3.1634]

46 The sun cure for surgical tuberculosis. *Br Med J* 1923; **2**: 111-112 [PMID: 20771236]

47 **Klip W**. The tuberculostatic action of vitamin D2. *Antonie Van Leeuwenhoek* 1952; **18**: 217-226 [PMID: 14944180 DOI: 10.1007/BF02538610]

48 **Davies PD**, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. *Thorax* 1985; **40**: 187-190 [PMID: 3872485 DOI: 10.1136/thx.40.3.187]

49 **Liu PT**, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006; **311**: 1770-1773 [PMID: 16497887 DOI: 10.1126/science.1123933]

50 **Zasloff M**. Fighting infections with vitamin D. *Nat Med* 2006; **12**: 388-390 [PMID: 16598282 DOI: 10.1038/nm0406-388]

51 **Laaksi I**, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, Ylikomi T. An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men. *Am J Clin Nutr* 2007; **86**: 714-717 [PMID: 17823437 DOI: 10.1093/ajcn/86.3.714]

52 **Bodnar LM**, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. *J Nutr* 2009; **139**: 1157-1161 [PMID: 19357214 DOI: 10.3945/jn.108.103168]

53 **Inamo Y**, Hasegawa M, Saito K, Hayashi R, Ishikawa T, Yoshino Y, Hashimoto K, Fuchigami T. Serum vitamin D concentrations and associated severity of acute lower respiratory tract infections in Japanese hospitalized children. *Pediatr Int* 2011; **53**: 199-201 [PMID: 21648117 DOI: 10.1111/j.1442-200x.2010.03224.x]

54 **Tiwari S**, Pratyush DD, Gupta B, Dwivedi A, Chaudhary S, Rayicherla RK, Gupta SK, Singh SK. Prevalence and severity of vitamin D deficiency in patients with diabetic foot infection. *Br J Nutr* 2013; **109**: 99-102 [PMID: 22715859 DOI: 10.1017/S0007114512000578]

55 **Terrier B**, Jehan F, Munteanu M, Geri G, Saadoun D, Sène D, Poynard T, Souberbielle JC, Cacoub P. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. *Rheumatology (Oxford)* 2012; **51**: 2083-2090 [PMID: 22908327 DOI: 10.1093/rheumatology/kes209]

56 **Pinzone MR**, Di Rosa M, Malaguarnera M, Madeddu G, Focà E, Ceccarelli G, d'Ettorre G, Vullo V, Fisichella R, Cacopardo B, Nunnari G. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. *Eur Rev Med Pharmacol Sci* 2013; **17**: 1218-1232 [PMID: 23690192]

57 **Abrishami A**, Dalili N, Mohammadi Torbati P, Asgari R, Arab-Ahmadi M, Behnam B, Sanei-Taheri M. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. *Eur J Nutr* 2021; **60**: 2249-2257 [PMID: 33123774 DOI: 10.1007/s00394-020-02411-0]

58 **Panagiotou G**, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, Boot CS, Stock N, Macfarlane J, Martineau AR, Burns G, Quinton R. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. *Clin Endocrinol (Oxf)* 2020; **93**: 508-511 [PMID: 32621392 DOI: 10.1111/cen.14276]

59 **Merzon E**, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, Frenkel-Morgenstern M. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS J* 2020; **287**: 3693-3702 [PMID: 32700398 DOI: 10.1111/febs.15495]

60 **Carpagnano GE**, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, Palumbo A, Di Gioia G, Valerio VN, Resta O. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J Endocrinol Invest* 2021; **44**: 765-771 [PMID: 32772324 DOI: 10.1007/s40618-020-01370-x]

61 **Meltzer DO**, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. *JAMA Netw Open* 2020; **3**: e2019722 [PMID: 32880651 DOI: 10.1001/jamanetworkopen.2020.19722]

62 **Van Schooten FJ**, Hirvonen A, Maas LM, De Mol BA, Kleinjans JC, Bell DA, Durrer JD. Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. *FASEB J* 1998; **12**: 1409-1417 [PMID: 9761785 DOI: 10.1096/fasebj.12.13.1409]

63 **Giovannucci E**, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med* 2008; **168**: 1174-1180 [PMID: 18541825 DOI: 10.1001/archinte.168.11.1174]

64 **Scragg R**, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. *Am J Hypertens* 2007; **20**: 713-719 [PMID: 17586404 DOI: 10.1016/j.amjhyper.2007.01.017]

65 **Pilz S**, Dobnig H, Fischer JE, Wellnitz B, Seelhorst U, Boehm BO, März W. Low vitamin d levels predict stroke in patients referred to coronary angiography. *Stroke* 2008; **39**: 2611-2613 [PMID: 18635847 DOI: 10.1161/STROKEAHA.107.513655]

66 **Xiang W**, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. *Am J Physiol Endocrinol Metab* 2005; **288**: E125-E132 [PMID: 15367398 DOI: 10.1152/ajpendo.00224.2004]

67 **Watson KE**, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation* 1997; **96**: 1755-1760 [PMID: 9323058 DOI: 10.1161/01.cir.96.6.1755]

68 **Sultan M**, Twito O, Tohami T, Ramati E, Neumark E, Rashid G. Vitamin D diminishes the high platelet aggregation of type 2 diabetes mellitus patients. *Platelets* 2019; **30**: 120-125 [PMID: 29313404 DOI: 10.1080/09537104.2017.1386298]

69 **Schleithoff SS**, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr* 2006; **83**: 754-759 [PMID: 16600924 DOI: 10.1093/ajcn/83.4.754]

70 **Kumar S**, Davies M, Zakaria Y, Mawer EB, Gordon C, Olukoga AO, Boulton AJ. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. *Postgrad Med J* 1994; **70**: 440-443 [PMID: 8029165 DOI: 10.1136/pgmj.70.824.440]

71 **Boucher BJ**, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. *Diabetologia* 1995; **38**: 1239-1245 [PMID: 8690178 DOI: 10.1007/BF00422375]

72 **Bell NH**, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. *J Clin Invest* 1985; **76**: 370-373 [PMID: 2991340 DOI: 10.1172/JCI111971]

73 **Ganji V**, Milone C, Cody MM, McCarty F, Wang YT. Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey. *Int Arch Med* 2010; **3**: 29 [PMID: 21067618 DOI: 10.1186/1755-7682-3-29]

74 **Zhu JL**, Luo WW, Cheng X, Li Y, Zhang QZ, Peng WX. Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. *Psychiatry Res* 2020; **288**: 112959 [PMID: 32335466 DOI: 10.1016/j.psychres.2020.112959]

75 **Wang T**, Shan L, Du L, Feng J, Xu Z, Staal WG, Jia F. Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis. *Eur Child Adolesc Psychiatry* 2016; **25**: 341-350 [PMID: 26514973 DOI: 10.1007/s00787-015-0786-1]

76 **Lv Z**, Qi H, Wang L, Fan X, Han F, Wang H, Bi S. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. *Neurol Sci* 2014; **35**: 1723-1730 [PMID: 24847960 DOI: 10.1007/s10072-014-1821-6]

77 **Smith MP**, Fletcher-Turner A, Yurek DM, Cass WA. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. *Neurochem Res* 2006; **31**: 533-539 [PMID: 16758362 DOI: 10.1007/s11064-006-9048-4]

78 **Mayne PE**, Burne THJ. Vitamin D in Synaptic Plasticity, Cognitive Function, and Neuropsychiatric Illness. *Trends Neurosci* 2019; **42**: 293-306 [PMID: 30795846 DOI: 10.1016/j.tins.2019.01.003]

79 **Almeras L**, Eyles D, Benech P, Laffite D, Villard C, Patatian A, Boucraut J, Mackay-Sim A, Μgrath J, Féron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. *Proteomics* 2007; **7**: 769-780 [PMID: 17295352 DOI: 10.1002/pmic.200600392]

80 **Eyles DW**, Smith S, Kinobe R, Hewison M, Μgrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. *J Chem Neuroanat* 2005; **29**: 21-30 [PMID: 15589699 DOI: 10.1016/j.jchemneu.2004.08.006]

81 **Phillips KM**, Ruggio DM, Horst RL, Minor B, Simon RR, Feeney MJ, Byrdwell WC, Haytowitz DB. Vitamin D and sterol composition of 10 types of mushrooms from retail suppliers in the United States. *J Agric Food Chem* 2011; **59**: 7841-7853 [PMID: 21663327 DOI: 10.1021/jf104246z]

82 **Libon F**, Cavalier E, Nikkels AF. Skin color is relevant to vitamin D synthesis. *Dermatology* 2013; **227**: 250-254 [PMID: 24134867 DOI: 10.1159/000354750]

83 **Jablonski NG**, Chaplin G. Colloquium paper: human skin pigmentation as an adaptation to UV radiation. *Proc Natl Acad Sci U S A* 2010; **107 Suppl 2**: 8962-8968 [PMID: 20445093 DOI: 10.1073/pnas.0914628107]

84 **Holick MF**. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. *Curr Opin Endocrinol Diabetes* 2002; **9**: 87-98

85 **Barger-Lux MJ**, Heaney RP. Effects of above average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. *J Clin Endocrinol Metab* 2002; **87**: 4952-4956 [PMID: 12414856 DOI: 10.1210/jc.2002-020636]

86 **Rockell JE**, Skeaff CM, Williams SM, Green TJ. Association between quantitative measures of skin color and plasma 25-hydroxyvitamin D. *Osteoporos Int* 2008; **19**: 1639-1642 [PMID: 18408879 DOI: 10.1007/s00198-008-0620-4]

87 **Epstein JH**. Photocarcinogenesis, skin cancer, and aging. *J Am Acad Dermatol* 1983; **9**: 487-502 [PMID: 6355213 DOI: 10.1016/s0190-9622(83)70160-x]

88 **Heaney RP**, Horst RL, Cullen DM, Armas LA. Vitamin D3 distribution and status in the body. *J Am Coll Nutr* 2009; **28**: 252-256 [PMID: 20150598 DOI: 10.1080/07315724.2009.10719779]

89 **Bouillon R**, Schuit F, Antonio L, Rastinejad F. Vitamin D Binding Protein: A Historic Overview. *Front Endocrinol (Lausanne)* 2019; **10**: 910 [PMID: 31998239 DOI: 10.3389/fendo.2019.00910]

90 **Haddad JG**, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* 1993; **91**: 2552-2555 [PMID: 8390483 DOI: 10.1172/JCI116492]

91 **Holmberg I**, Berlin T, Ewerth S, Björkhem I. 25-Hydroxylase activity in subcellular fractions from human liver. Evidence for different rates of mitochondrial hydroxylation of vitamin D2 and D3. *Scand J Clin Lab Invest* 1986; **46**: 785-790 [PMID: 3026027 DOI: 10.3109/00365518609084051]

92 **Armas LA**, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. *J Clin Endocrinol Metab* 2004; **89**: 5387-5391 [PMID: 15531486 DOI: 10.1210/jc.2004-0360]

93 **Zarei A**, Hulley PA, Sabokbar A, Javaid MK, Morovat A. 25-Hydroxy- and 1α,25-Dihydroxycholecalciferol Have Greater Potencies than 25-Hydroxy- and 1α,25-Dihydroxyergocalciferol in Modulating Cultured Human and Mouse Osteoblast Activities. *PLoS One* 2016; **11**: e0165462 [PMID: 27893751 DOI: 10.1371/journal.pone.0165462]

94 **Jones G**, Byrnes B, Palma F, Segev D, Mazur Y. Displacement potency of vitamin D2 analogs in competitive protein-binding assays for 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3, and 1,25-dihydroxyvitamin D3. *J Clin Endocrinol Metab* 1980; **50**: 773-775 [PMID: 6965943 DOI: 10.1210/jcem-50-4-773]

95 **Holick MF**, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannenbaum AD. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab* 2008; **93**: 677-681 [PMID: 18089691 DOI: 10.1210/jc.2007-2308]

96 **Trang HM**, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. *Am J Clin Nutr* 1998; **68**: 854-858 [PMID: 9771862 DOI: 10.1093/ajcn/68.4.854]

97 **Romagnoli E**, Mascia ML, Cipriani C, Fassino V, Mazzei F, D'Erasmo E, Carnevale V, Scillitani A, Minisola S. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. *J Clin Endocrinol Metab* 2008; **93**: 3015-3020 [PMID: 18492750 DOI: 10.1210/jc.2008-0350]

98 **Heaney RP**, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. *J Clin Endocrinol Metab* 2011; **96**: E447-E452 [PMID: 21177785 DOI: 10.1210/jc.2010-2230]

99 **Glendenning P**, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, Inderjeeth CA, Vasikaran SD, Taranto M, Musk AA, Fraser WD. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. *Bone* 2009; **45**: 870-875 [PMID: 19631774 DOI: 10.1016/j.bone.2009.07.015]

100 **Shieh A**, Chun RF, Ma C, Witzel S, Meyer B, Rafison B, Swinkels L, Huijs T, Pepkowitz S, Holmquist B, Hewison M, Adams JS. Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance. *J Clin Endocrinol Metab* 2016; **101**: 3070-3078 [PMID: 27192696 DOI: 10.1210/jc.2016-1871]

101 **Tripkovic L**, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr* 2012; **95**: 1357-1364 [PMID: 22552031 DOI: 10.3945/ajcn.111.031070]

102 **Cipriani C**, Romagnoli E, Pepe J, Russo S, Carlucci L, Piemonte S, Nieddu L, McMahon DJ, Singh R, Minisola S. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. *J Clin Endocrinol Metab* 2013; **98**: 2709-2715 [PMID: 23766519 DOI: 10.1210/jc.2013-1586]

103 **Malabanan A**, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. *Lancet* 1998; **351**: 805-806 [PMID: 9519960 DOI: 10.1016/s0140-6736(05)78933-9]

104 **Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D, Calcium.** Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Washington (DC): National Academies Press (US), 2011

105 **Chapuy MC**, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. *Osteoporos Int* 1997; **7**: 439-443 [PMID: 9425501 DOI: 10.1007/s001980050030]

106 **Heaney RP**. Functional indices of vitamin D status and ramifications of vitamin D deficiency. *Am J Clin Nutr* 2004; **80**: 1706S-1709S [PMID: 15585791 DOI: 10.1093/ajcn/80.6.1706S]

107 **Melamed ML**, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med* 2008; **168**: 1629-1637 [PMID: 18695076 DOI: 10.1001/archinte.168.15.1629]

108 **Durup D**, Jørgensen HL, Christensen J, Tjønneland A, Olsen A, Halkjær J, Lind B, Heegaard AM, Schwarz P. A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. *J Clin Endocrinol Metab* 2015; **100**: 2339-2346 [PMID: 25710567 DOI: 10.1210/jc.2014-4551]

109 **Bischoff-Ferrari HA**, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006; **84**: 18-28 [PMID: 16825677 DOI: 10.1093/ajcn/84.1.18]

110 **Adams JS**, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. *Ann Intern Med* 1997; **127**: 203-206 [PMID: 9245225 DOI: 10.7326/0003-4819-127-3-199708010-00004]

111 **Aloia JF**, Dhaliwal R, Shieh A, Mikhail M, Fazzari M, Ragolia L, Abrams SA. Vitamin D supplementation increases calcium absorption without a threshold effect. *Am J Clin Nutr* 2014; **99**: 624-631 [PMID: 24335055 DOI: 10.3945/ajcn.113.067199]

112 **Huang J**, Ou HY, Karnchanasorn R, Chiu KC. Clinical implication of vitamin D threshold. *Am J Clin Nutr* 2014; **100**: 295-296 [PMID: 24951577 DOI: 10.3945/ajcn.114.087171]

113 **Ou HY**, Karnchanasorn R, Lee LZ, Chiu KC. Interaction of BMI with vitamin D and insulin sensitivity. *Eur J Clin Invest* 2011; **41**: 1195-1201 [PMID: 21434896 DOI: 10.1111/j.1365-2362.2011.02525.x]

114 **Heaney RP**. Nutrition and chronic disease. *Mayo Clin Proc* 2006; **81**: 297-299 [PMID: 16529131 DOI: 10.4065/81.3.297]

115 **Ilahi M**, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. *Am J Clin Nutr* 2008; **87**: 688-691 [PMID: 18326608 DOI: 10.1093/ajcn/87.3.688]

116 **Ghazi AA**, Hosseinpanah F, M Ardakani E, Ghazi S, Hedayati M, Azizi F. Effects of different doses of oral cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in schoolchildren. *Eur J Clin Nutr* 2010; **64**: 1415-1422 [PMID: 20823895 DOI: 10.1038/ejcn.2010.169]

117 **Carnes J**, Quinn S, Nelson M, Jones G, Winzenberg T. Intermittent high-dose vitamin D corrects vitamin D deficiency in adolescents: a pilot study. *Eur J Clin Nutr* 2012; **66**: 530-532 [PMID: 22190133 DOI: 10.1038/ejcn.2011.204]

118 **Sanders KM**, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* 2010; **303**: 1815-1822 [PMID: 20460620 DOI: 10.1001/jama.2010.594]

119 **Leventis P**, Kiely PD. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. *Scand J Rheumatol* 2009; **38**: 149-153 [PMID: 18991184 DOI: 10.1080/03009740802419081]

120 **Rossini M**, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, Adami S. Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃. *J Clin Endocrinol Metab* 2012; **97**: E622-E626 [PMID: 22298802 DOI: 10.1210/jc.2011-2448]

121 **von Restorff C**, Bischoff-Ferrari HA, Theiler R. High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. *Bone* 2009; **45**: 747-749 [PMID: 19539796 DOI: 10.1016/j.bone.2009.06.012]

122 **Tellioglu A**, Basaran S, Guzel R, Seydaoglu G. Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly. *Maturitas* 2012; **72**: 332-338 [PMID: 22613271 DOI: 10.1016/j.maturitas.2012.04.011]

123 **Witham MD**, Dove FJ, Sugden JA, Doney AS, Struthers AD. The effect of vitamin D replacement on markers of vascular health in stroke patients - a randomised controlled trial. *Nutr Metab Cardiovasc Dis* 2012; **22**: 864-870 [PMID: 21194910 DOI: 10.1016/j.numecd.2010.11.001]

124 **Ish-Shalom S**, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. *J Clin Endocrinol Metab* 2008; **93**: 3430-3435 [PMID: 18544622 DOI: 10.1210/jc.2008-0241]

125 **Fu L**, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. *Clin Biochem* 2009; **42**: 1174-1177 [PMID: 19302999 DOI: 10.1016/j.clinbiochem.2009.03.008]

126 **Wang TJ**, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* 2010; **376**: 180-188 [PMID: 20541252 DOI: 10.1016/S0140-6736(10)60588-0]

127 **Hsu S**, Hoofnagle AN, Gupta DK, Gutierrez OM, Peralta CA, Shea S, Allen NB, Burke G, Michos ED, Ix JH, Siscovick D, Psaty BM, Watson KE, Kestenbaum B, de Boer IH, Robinson-Cohen C. Race, Ancestry, and Vitamin D Metabolism: The Multi-Ethnic Study of Atherosclerosis. *J Clin Endocrinol Metab* 2020; **105**: e4337-e4350 [PMID: 32869845 DOI: 10.1210/clinem/dgaa612]

128 **Clemens TL**, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. *Lancet* 1982; **1**: 74-76 [PMID: 6119494 DOI: 10.1016/s0140-6736(82)90214-8]

129 **Webb AR**, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. *J Clin Endocrinol Metab* 1988; **67**: 373-378 [PMID: 2839537 DOI: 10.1210/jcem-67-2-373]

130 **Gangloff A**, Bergeron J, Lemieux I, Després JP. Changes in circulating vitamin D levels with loss of adipose tissue. *Curr Opin Clin Nutr Metab Care* 2016; **19**: 464-470 [PMID: 27537278 DOI: 10.1097/MCO.0000000000000315]

131 **Holick MF**, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; **96**: 1911-1930 [PMID: 21646368 DOI: 10.1210/jc.2011-0385]

132 **Vieth R**. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999; **69**: 842-856 [PMID: 10232622 DOI: 10.1093/ajcn/69.5.842]

133 **Mulligan GB**, Licata A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. *J Bone Miner Res* 2010; **25**: 928-930 [PMID: 20200983 DOI: 10.1002/jbmr.67]

134 **Dutta D**, Mondal SA, Choudhuri S, Maisnam I, Hasanoor Reza AH, Bhattacharya B, Chowdhury S, Mukhopadhyay S. Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India. *Diabetes Res Clin Pract* 2014; **103**: e18-e23 [PMID: 24456991 DOI: 10.1016/j.diabres.2013.12.044]

135 **Niroomand M**, Fotouhi A, Irannejad N, Hosseinpanah F. Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. *Diabetes Res Clin Pract* 2019; **148**: 1-9 [PMID: 30583032 DOI: 10.1016/j.diabres.2018.12.008]

136 **Wagner H**, Alvarsson M, Mannheimer B, Degerblad M, Östenson CG. No Effect of High-Dose Vitamin D Treatment on β-Cell Function, Insulin Sensitivity, or Glucose Homeostasis in Subjects With Abnormal Glucose Tolerance: A Randomized Clinical Trial. *Diabetes Care* 2016; **39**: 345-352 [PMID: 26786573 DOI: 10.2337/dc15-1057]

137 **Oosterwerff MM**, Eekhoff EM, Van Schoor NM, Boeke AJ, Nanayakkara P, Meijnen R, Knol DL, Kramer MH, Lips P. Effect of moderate-dose vitamin D supplementation on insulin sensitivity in vitamin D-deficient non-Western immigrants in the Netherlands: a randomized placebo-controlled trial. *Am J Clin Nutr* 2014; **100**: 152-160 [PMID: 24898240 DOI: 10.3945/ajcn.113.069260]

138 **Pittas AG**, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M; D2d Research Group. Vitamin D Supplementation and Prevention of Type 2 Diabetes. *N Engl J Med* 2019; **381**: 520-530 [PMID: 31173679 DOI: 10.1056/NEJMoa1900906]

139 **Davidson MB**, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. *Diabetes Care* 2013; **36**: 260-266 [PMID: 23033239 DOI: 10.2337/dc12-1204]

140 **Jorde R**, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I, Fuskevåg OM, Figenschau Y, Hutchinson MY. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes. *J Clin Endocrinol Metab* 2016; **101**: 1647-1655 [PMID: 26829443 DOI: 10.1210/jc.2015-4013]

141 **Barengolts E**, Manickam B, Eisenberg Y, Akbar A, Kukreja S, Ciubotaru I. Effect of high-dose vitamin D repletion on glycemic control in african-american males with prediabetes and hypovitaminosis d. *Endocr Pract* 2015; **21**: 604-612 [PMID: 25716637 DOI: 10.4158/EP14548.OR]

142 **Jorde R**, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. *Eur J Nutr* 2009; **48**: 349-354 [PMID: 19370371 DOI: 10.1007/s00394-009-0020-3]

143 **Jorde R**, Strand Hutchinson M, Kjærgaard M, Sneve M, Grimnes G. Supplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Tromsø. *ISRN Endocrinol* 2013; **2013**: 348705 [PMID: 23577264 DOI: 10.1155/2013/348705]

144 **Norman AW**, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. *Science* 1980; **209**: 823-825 [PMID: 6250216 DOI: 10.1126/science.6250216]

145 **Clark SA**, Stumpf WE, Sar M, DeLuca HF, Tanaka Y. Target cells for 1,25 dihydroxyvitamin D3 in the pancreas. *Cell Tissue Res* 1980; **209**: 515-520 [PMID: 6996826 DOI: 10.1007/BF00234764]

146 **Clark SA**, Stumpf WE, Sar M. Effect of 1,25 dihydroxyvitamin D3 on insulin secretion. *Diabetes* 1981; **30**: 382-386 [PMID: 7014306 DOI: 10.2337/diab.30.5.382]

147 **Chertow BS**, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. *Endocrinology* 1983; **113**: 1511-1518 [PMID: 6352248 DOI: 10.1210/endo-113-4-1511]

148 **Kadowaki S**, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. *J Clin Invest* 1984; **73**: 759-766 [PMID: 6323527 DOI: 10.1172/JCI111269]

149 **Kadowaki S**, Norman AW. Time course study of insulin secretion after 1,25-dihydroxyvitamin D3 administration. *Endocrinology* 1985; **117**: 1765-1771 [PMID: 3899614 DOI: 10.1210/endo-117-5-1765]

150 **Cade C**, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. *Endocrinology* 1986; **119**: 84-90 [PMID: 3013599 DOI: 10.1210/endo-119-1-84]

151 **Cade C**, Norman AW. Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. *Endocrinology* 1987; **120**: 1490-1497 [PMID: 3549262 DOI: 10.1210/endo-120-4-1490]

152 **Zeitz U**, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. *FASEB J* 2003; **17**: 509-511 [PMID: 12551842 DOI: 10.1096/fj.02-0424fje]

153 **Pepaj M**, Bredahl MK, Gjerlaugsen N, Bornstedt ME, Thorsby PM. Discovery of novel vitamin D-regulated proteins in INS-1 cells: a proteomic approach. *Diabetes Metab Res Rev* 2015; **31**: 481-491 [PMID: 25449168 DOI: 10.1002/dmrr.2629]

154 **Bornstedt ME**, Gjerlaugsen N, Olstad OK, Berg JP, Bredahl MK, Thorsby PM. Vitamin D metabolites influence expression of genes concerning cellular viability and function in insulin producing β-cells (INS1E). *Gene* 2020; **746**: 144649 [PMID: 32251702 DOI: 10.1016/j.gene.2020.144649]

155 **Cheng Q**, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. *Diabetologia* 2011; **54**: 2077-2081 [PMID: 21424540 DOI: 10.1007/s00125-011-2100-1]

156 **Lahbib A**, Ghodbane S, Louchami K, Sener A, Sakly M, Abdelmelek H. Effects of vitamin D on insulin secretion and glucose transporter GLUT2 under static magnetic field in rat. *Environ Sci Pollut Res Int* 2015; **22**: 18011-18016 [PMID: 26169817 DOI: 10.1007/s11356-015-4844-5]

157 **Jayanarayanan S**, Anju TR, Smijin S, Paulose CS. Vitamin D3 supplementation increases insulin level by regulating altered IP3 and AMPA receptor expression in the pancreatic islets of streptozotocin-induced diabetic rat. *J Nutr Biochem* 2015; **26**: 1041-1049 [PMID: 26054778 DOI: 10.1016/j.jnutbio.2015.04.011]

158 **Kuo T**, Damle M, González BJ, Egli D, Lazar MA, Accili D. Induction of α cell-restricted Gc in dedifferentiating β cells contributes to stress-induced β-cell dysfunction. *JCI Insight* 2019; **5**: e128351 [PMID: 31120862 DOI: 10.1172/jci.insight.128351]

159 **He D**, Wang Y, Liu R, He A, Li S, Fu X, Zhou Z. 1,25(OH)2D3 Activates Autophagy to Protect against Oxidative Damage of INS-1 Pancreatic Beta Cells. *Biol Pharm Bull* 2019; **42**: 561-567 [PMID: 30930416 DOI: 10.1248/bpb.b18-00395]

160 **Guareschi ZM**, Valcanaia AC, Ceglarek VM, Hotz P, Amaral BK, de Souza DW, de Souza TA, Nardelli T, Ferreira TR, Leite NC, Lubackzeuski C, de O Emilio HR, Grassiolli S. The effect of chronic oral vitamin D supplementation on adiposity and insulin secretion in hypothalamic obese rats. *Br J Nutr* 2019; **121**: 1334-1344 [PMID: 30924427 DOI: 10.1017/S0007114519000667]

161 **Kjalarsdottir L**, Tersey SA, Vishwanath M, Chuang JC, Posner BA, Mirmira RG, Repa JJ. 1,25-Dihydroxyvitamin D3 enhances glucose-stimulated insulin secretion in mouse and human islets: a role for transcriptional regulation of voltage-gated calcium channels by the vitamin D receptor. *J Steroid Biochem Mol Biol* 2019; **185**: 17-26 [PMID: 30071248 DOI: 10.1016/j.jsbmb.2018.07.004]

162 **Park S**, Kim DS, Kang S. Vitamin D deficiency impairs glucose-stimulated insulin secretion and increases insulin resistance by reducing PPAR-γ expression in nonobese Type 2 diabetic rats. *J Nutr Biochem* 2016; **27**: 257-265 [PMID: 26522682 DOI: 10.1016/j.jnutbio.2015.09.013]

163 **Mazzone G**, Morisco C, Lembo V, D'Argenio G, D'Armiento M, Rossi A, Giudice CD, Trimarco B, Caporaso N, Morisco F. Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats. *United European Gastroenterol J* 2018; **6**: 1056-1064 [PMID: 30228894 DOI: 10.1177/2050640618774140]

164 **Dong B**, Zhou Y, Wang W, Scott J, Kim K, Sun Z, Guo Q, Lu Y, Gonzales NM, Wu H, Hartig SM, York RB, Yang F, Moore DD. Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice. *Hepatology* 2020; **71**: 1559-1574 [PMID: 31506976 DOI: 10.1002/hep.30937]

165 **Sadek KM**, Shaheen H. Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats. *Pharm Biol* 2014; **52**: 591-596 [PMID: 24251869 DOI: 10.3109/13880209.2013.854812]

166 **Sisley SR**, Arble DM, Chambers AP, Gutierrez-Aguilar R, He Y, Xu Y, Gardner D, Moore DD, Seeley RJ, Sandoval DA. Hypothalamic Vitamin D Improves Glucose Homeostasis and Reduces Weight. *Diabetes* 2016; **65**: 2732-2741 [PMID: 27217488 DOI: 10.2337/db16-0309]

167 **Schnell DM**, Walton RG, Vekaria HJ, Sullivan PG, Bollinger LM, Peterson CA, Thomas DT. Vitamin D produces a perilipin 2-dependent increase in mitochondrial function in C2C12 myotubes. *J Nutr Biochem* 2019; **65**: 83-92 [PMID: 30658160 DOI: 10.1016/j.jnutbio.2018.11.002]

168 **Jefferson GE**, Schnell DM, Thomas DT, Bollinger LM. Calcitriol concomitantly enhances insulin sensitivity and alters myocellular lipid partitioning in high fat-treated skeletal muscle cells. *J Physiol Biochem* 2017; **73**: 613-621 [PMID: 28980208 DOI: 10.1007/s13105-017-0595-8]

169 **Hesse M**, Fröhlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. *Matrix Biol* 2007; **26**: 75-84 [PMID: 17123805 DOI: 10.1016/j.matbio.2006.10.003]

170 **Boucher BJ**. Does vitamin D status contribute to caveolin-1-mediated insulin sensitivity in skeletal muscle? *Diabetologia* 2009; **52**: 2240 [PMID: 19672573 DOI: 10.1007/s00125-009-1478-5]

171 **Wu YY**, Yu T, Zhang XH, Liu YS, Li F, Wang YY, Wang YY, Gong P. 1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling. *J Steroid Biochem Mol Biol* 2012; **132**: 112-119 [PMID: 22595150 DOI: 10.1016/j.jsbmb.2012.05.002]

172 **Chen S**, Villalta SA, Agrawal DK. FOXO1 Mediates Vitamin D Deficiency-Induced Insulin Resistance in Skeletal Muscle. *J Bone Miner Res* 2016; **31**: 585-595 [PMID: 26462119 DOI: 10.1002/jbmr.2729]

173 **Oh J**, Riek AE, Darwech I, Funai K, Shao J, Chin K, Sierra OL, Carmeliet G, Ostlund RE Jr, Bernal-Mizrachi C. Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. *Cell Rep* 2015; **10**: 1872-1886 [PMID: 25801026 DOI: 10.1016/j.celrep.2015.02.043]

174 **Ni W**, Glenn DJ, Gardner DG. Tie-2Cre mediated deletion of the vitamin D receptor gene leads to improved skeletal muscle insulin sensitivity and glucose tolerance. *J Steroid Biochem Mol Biol* 2016; **164**: 281-286 [PMID: 26369613 DOI: 10.1016/j.jsbmb.2015.09.017]

175 **Knowler WC**, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; **346**: 393-403 [PMID: 11832527 DOI: 10.1056/NEJMoa012512]

176 **Knowler WC**, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. *Diabetes* 2005; **54**: 1150-1156 [PMID: 15793255 DOI: 10.2337/diabetes.54.4.1150]

177 **Karnchanasorn R**, Ou HY, Chiu KC. Proposed Guidelines for Future Vitamin D Studies. *JAMA Intern Med* 2016; **176**: 280-281 [PMID: 26830241 DOI: 10.1001/jamainternmed.2015.7974]

178 **Chiu KC**, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 2004; **79**: 820-825 [PMID: 15113720 DOI: 10.1093/ajcn/79.5.820]

179 **Karnchanasorn R**, Ou HY, Chiu KC. Plasma 25-hydroxyvitamin D levels are favorably associated with β-cell function. *Pancreas* 2012; **41**: 863-868 [PMID: 22258069 DOI: 10.1097/MPA.0b013e31823c947c]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict-of-interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Endocrine Society; American Diabetes Association; American College of Endocrinology; American Association of Clinical Endocrinology; American College of Physicians

**Peer-review started:** January 26, 2021

**First decision:** May 3, 2021

**Article in press:** August 5, 2021

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yang L **S-Editor:** Liu M **L-Editor:** A **P-Editor:** Guo X

**Figure Legends**



**Figure 1 Vitamin D publications from 1922 to 2020.** Data were obtained from PubMed (https://pubmed.ncbi.nlm.nih.gov/) accessed on October 20, 2020.

**Table 1 Vitamin D as a hormone: Comparison of the pituitary-thyroid and parathyroid hormone-vitamin D axes**

|  |  |  |
| --- | --- | --- |
|  | **Pituitary-thyroid axis** | **Parathyroid-vitamin D axis** |
| Organ(s) | Thyroid glands | Skin/liver/kidney |
| Source compound | Iodine, tyrosine | Cholecalciferol (cholesterol), ergocalciferol |
| Prehormone | Levothyroxine, T1/2 = 6-7 d | 25-hydoxyvitamin D2/D3, T1/2 = 13-17 d |
| Active hormone | Triiodothyronine, T1/2 = 14-24 h | 1,25-dihydroxyvitamin D2/D3, T1/2 = 10-20 h |
| Transportation | Thyroxine binding globulin | Vitamin D binding protein |
| Receptor | Thyroid hormone receptor | Vitamin D receptor |
| Stimulating factor | Thyroid stimulating hormone | Parathyroid hormone |
| Effect | Energy homeostasis | Calcium homeostasis |

**Table 2 Vitamin D content of selected foods**

|  |  |  |
| --- | --- | --- |
| **Food** | **Per serving** | **Percent DV** |
|  | **IU** | **μg** |  |
| Cod liver oil, 1 tablespoon | 1360 | 34.00 | 170 |
| Trout (rainbow), farmed, cooked, 3 ounces | 645 | 16.13 | 81 |
| Salmon (sockeye), cooked, 3 ounces | 570 | 14.25 | 71 |
| Mushrooms, white, raw, sliced, exposed to UV light, 1/2 cup | 366 | 9.15 | 46 |
| Milk, 2% milkfat, vitamin D fortified, 1 cup | 120 | 3.00 | 15 |
| Soy, almond, and oat milks, vitamin D fortified, various brands, 1 cup | 100-144 | 2.50-3.60 | 13-18 |
| Ready-to-eat cereal, fortified with 10% of the DV for vitamin D, 1 serving | 80 | 2.00 | 10 |
| Sardines (Atlantic), canned in oil, drained, 2 sardines | 46 | 1.15 | 6 |
| Egg, 1 large, scrambled (Vitamin D is in the yolk) | 44 | 1.10 | 6 |
| Liver, beef, braised, 3 ounces | 42 | 1.05 | 5 |
| Tuna fish (light), canned in water, drained, 3 ounces | 40 | 1.00 | 5 |
| Cheese, cheddar, 1 ounce | 12 | 0.30 | 2 |
| Mushrooms, portabella, raw, diced, ½ cup | 4 | 0.10 | 1 |
| Chicken breast, roasted, 3 ounces | 4 | 0.10 | 1 |
| Beef, ground, 90% lean, broiled, 3 ounces | 1.7 | 0.04 | 0 |

Adapted from: <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#en25>. The Food and Drug Administration developed daily values (DVs) to help consumers compare the nutrient contents of foods and dietary supplements within the context of a total diet. The DV for vitamin D on the new Nutrition Facts and Supplement Facts labels used for the values in Table 2 is 20 μg (800 IU) for adults and children aged 4 years and older. Foods providing 20% or more of the DV are considered to be high sources of a nutrient, but foods providing lower percentages of the DV also contribute to a healthful diet. DV: Daily value.

**Table 3 Comparison of transportation and metabolism of vitamin D3 *vs* D2**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Symbol**  | **Name (chromosome location)** | **Function** | **D3/D2** |
| Haddad *et al*[90], 1993 | VBP | Vitamin D binding protein (4q12-q13) | Vitamin D transportation | 1.14 |
| Holmberg *et al*[91], 1986  | *CYP2R1* | 25-hydroxylase (11p15.2) | Conversion of vitamin D to 25-hydroxy vitamin D | 5.0 |
| Zarei *et al*[93], 2016 | *CYP27B1* | 1alpha-hydroxylase (12q13.1-q13.3) | Conversion of 25(OH)D to 1,25(OH)2D | 2.4 |
| Jones *et al*[94], 1980 | VDR | Vitamin D receptor (7q36)  | Receptor for vitamin D | 1.3 |

**Table 4 Recommended daily vitamin D intake as promulgated by selected organizations and agencies**

|  |  |  |
| --- | --- | --- |
| **Organization** | **Daily intake** | **Goal** |
|  | **IU** | **μg** | **ng/mL** | **nmol/L** |
| Institute of Medicine | 600-800 | 15-20 | > 20 (20-50) | > 50 (50-125) |
| Agency of Healthcare Research and Quality, Department of Health and Human Services | > 1000 | > 25 | > 30 | > 75 |
| Office of Dietary Supplements, NIH | 600-800 | 15-20 | 20-50 | 50-125 |
| National Osteoporosis Foundation | 800-1000 | 20-25 | > 30 | > 75 |
| American Association of Clinical Endocrinologists | 1000-2000 | 25-50 | 30-60 | 75-150 |
| Endocrine Society | 1500-2000 | 37.5-50 | 30-100 | 75-250 |

**Table 5 Diminished response of intestinal calcium absorption in response to increasing vitamin D supplementation**

|  |  |  |
| --- | --- | --- |
| **Daily vitamin D supplementation**  | **Observed increase in calcium absorption** | **Estimated increase in calcium absorption per 1000 IU (25 μg)** |
| IU | μg |  |  |
| 800 | 20 | 3.90% | 4.88% |
| 2000 | 50 | 5.00% | 2.50% |
| 4000 | 100 | 6.70% | 1.68% |

**Table 6 Major loci associated with changes in serum 25-hydroxyvitamin D concentration**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Chromosome** | **SNP** | **Gene symbol** | **Protein** | ***P* value** |
| 4p12 | rs2282679 | GC | Vitamin D binding protein | 1.9 × 10-109 |
| 11q12 | rs12785878 | DHCR7 | 7-dehydrocholsterol reductase | 2.1 × 10-27 |
| 11p15 | rs10741657 | CYP2R1 | 1-alpha-hydroxylase | 3.3 × 10-20 |
| 20q13 | rs6013897 | CYP24A1 | 1,25-dihydroxyvitamin D3 24-hydroxylase | 6.0 × 10-10 |

Adapted from Wang *et al*[126]. SNP: Single nucleotide polymorphism.

**Table 7 Vitamin D supplementation versus vitamin D replacement therapy**

|  |  |  |
| --- | --- | --- |
|  | **Vitamin D supplement** | **Vitamin D replacement therapy** |
| Target goal | Bone health | Beyond bone health |
| Target 25-hydroxyvitamin D level | > 20 ng/mL (50 nmol/L) | > 30 ng/mL (75 nmol/L) |
| Initial testing for 25-hydroxyvitamin D level | No | Yes |
| Concern of over-replacement | Yes | Yes |
| Follow-up testing for 25-hydroxyvitamin D level | No | Yes |
| Dose adjustment | No | Yes |
| Approach | Public health | Individualized |

**Table 8 Preventive trials of vitamin D supplementation to prevent the development of type 2 diabetes**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country Race/****ethnicity** | **Placebo control** | **Intervention** | **Dose** | **Frequency** | **Duration** | **Diabetes prevention** |
| ***n*** | **25(OH)D nmol/L** | ***n*** | **25(OH)D nmol/L** |
| **Initial** | **Final** | **Initial** | **Final** |
| Dutta *et al*[134], 20141 | IndiaAsian Indian  | 49 | 45 | 44 | 55 | 43 | 89 | 1500 μg | Weekly X 8, monthly | 1 yr | Positive2 |
| Niroomand *et al*[135], 2019 | IranIranian | 83 | 32 | 40 | 83 | 31 | 90 | 1250 μg | Weekly for 3 mo, monthly | 6 mo | Positive3 |
| Wagner *et al*[136], 20164 | Sweden | 22 | 47 | 46 | 21 | 42 | 83 | 750 μg | weekly | 8 wk | Negative |
| Oosterwerff *et al*[137], 2014 | HollandNon-Western | 65 | 22 | 23 | 65 | 25 | 60 | 30 μg | daily | 16 wk | Negative |
| Barengolts *et al*[141], 20155 | United States African American | 86 | 35 | 50 | 87 | 37 | 120 | 1250 μg | weekly | 12 m | Negative |
| Davidson *et al*[139], 20136 | United States Latino and African American | 53 | 55 | 60 | 56 | 55 | 167 | 2222 μg  | weekly | 12 mo | Negative |
| Jorde *et al*[140], 2016 | Norway | 255 | 61 | 64 | 256 | 60 | 110 | 500 μg | weekly | 5 yr | Negative |
| Pittas *et al*[138], 2019 | United States mixed | 1212 | 70 | 72 | 1211 | 69 | 136 | 100 μg | daily | 24 mo | Negative |

1This study was an open label randomized design, instead of randomized placebo-control design as other studies.

2Intervention is associated with significantly lower progression to diabetes (11% *vs* 27%; *P* = 0.04) and higher reversal to normoglycemia (43% *vs* 20%; *P* = 0.02).

3The rate of progression toward diabetes was significantly lower in the intervention group (3% *vs* 28%; *P* = 0.002).

4Meadian 25-hydroxyvitamin was provided, rather than mean 25-hydroxyvitamin D as in other studies.

5Ergocalciferol was used, rather than cholecalciferol in other studies.

6Weekly dose of cholecalciferol was adjusted to titrate serum 25-hydroxyvitamin D between 162 nmol/L and 200 nmol/L.

**Table 9 Calculated sample size requirement to detect an improvement in insulin sensitivity based on a baseline serum 25-hydroxyvitamin D concentration of 40 ng/mL (100 nmol/L) and a power of 0.80 and alpha of 0.05**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Initial serum 25-hydroxy-****vitamin D concentration** | **Estimated insulin sensitivity index****(μM/min/m2/pM)** | **Improvement in insulin sensitivity index with postintervention Serum 25-hydroxyvitamin D concentration 40 ng/mL (100 nmol/L)** | **Diabetes reduction based on the Diabetes Prevention Program** | **Sample size** |
| **ng/mL** | **nmol/L** |
| 10 | 25 | 4.1326 | 0.8664 | 0.4361 | 340 |
| 15 | 37 | 5.4144 | 0.4246 | 0.2118 | 1602 |
| 20 | 50 | 6.2812 | 0.2280 | 0.1121 | 5934 |
| 25 | 62 | 6.8674 | 0.1232 | 0.0589 | 21878 |
| 30 | 75 | 7.2638 | 0.0619 | 0.0278 | 99260 |
| 35 | 87 | 7.5319 | 0.0241 | 0.0086 | 1041162 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**